SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison
Neutralizing antibodies (NAs) are key immunological markers and are part of the humoral response of the adaptive immune system. NA assays determine the presence of functional antibodies to prevent SARS-CoV-2 infection. We performed a real-world evidence study to detect NAs that confer protection aga...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/6/1194 |
| _version_ | 1797612421955715072 |
|---|---|
| author | Fernando Alcorta-Nuñez Diana Cristina Pérez-Ibave Carlos Horacio Burciaga-Flores Miguel Ángel Garza Moisés González-Escamilla Patricia Rodríguez-Niño Juan Francisco González-Guerrero Adelina Alcorta-Garza Oscar Vidal-Gutiérrez Genaro A. Ramírez-Correa María Lourdes Garza-Rodríguez |
| author_facet | Fernando Alcorta-Nuñez Diana Cristina Pérez-Ibave Carlos Horacio Burciaga-Flores Miguel Ángel Garza Moisés González-Escamilla Patricia Rodríguez-Niño Juan Francisco González-Guerrero Adelina Alcorta-Garza Oscar Vidal-Gutiérrez Genaro A. Ramírez-Correa María Lourdes Garza-Rodríguez |
| author_sort | Fernando Alcorta-Nuñez |
| collection | DOAJ |
| description | Neutralizing antibodies (NAs) are key immunological markers and are part of the humoral response of the adaptive immune system. NA assays determine the presence of functional antibodies to prevent SARS-CoV-2 infection. We performed a real-world evidence study to detect NAs that confer protection against SARS-CoV-2 after the application of five vaccines (Pfizer/BioNTech, AstraZeneca, Sinovac, Moderna, and CanSino) in the Mexican population. Side effects of COVID-19 vaccines and clinical and demographic factors associated with low immunogenicity were also evaluated. A total of 242 SARS-CoV-2-vaccinated subjects were recruited. Pfizer/BioNTech and Moderna proved the highest percentage of inhibition in a mono-vaccine scheme. Muscular pain, headache, and fatigue were the most common adverse events. None of the patients reported severe adverse events. We found an estimated contagion-free time of 207 (IQR: 182–231) and 187 (IQR: 184–189) days for Pfizer/BioNTech and CanSino in 12 cases in each group. On the basis of our results, we consider that the emerging vaccination strategy in Mexico is effective and safe. |
| first_indexed | 2024-03-11T06:41:00Z |
| format | Article |
| id | doaj.art-93f0c37cb75d4894b996ebd06dbde01f |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T06:41:00Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-93f0c37cb75d4894b996ebd06dbde01f2023-11-17T10:35:38ZengMDPI AGDiagnostics2075-44182023-03-01136119410.3390/diagnostics13061194SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine ComparisonFernando Alcorta-Nuñez0Diana Cristina Pérez-Ibave1Carlos Horacio Burciaga-Flores2Miguel Ángel Garza3Moisés González-Escamilla4Patricia Rodríguez-Niño5Juan Francisco González-Guerrero6Adelina Alcorta-Garza7Oscar Vidal-Gutiérrez8Genaro A. Ramírez-Correa9María Lourdes Garza-Rodríguez10Servicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoDepartment of Molecular Science, U.T. Health Rio Grande Valley, McAllen, TX 78503, USAServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoDepartment of Molecular Science, U.T. Health Rio Grande Valley, McAllen, TX 78503, USAServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, MexicoNeutralizing antibodies (NAs) are key immunological markers and are part of the humoral response of the adaptive immune system. NA assays determine the presence of functional antibodies to prevent SARS-CoV-2 infection. We performed a real-world evidence study to detect NAs that confer protection against SARS-CoV-2 after the application of five vaccines (Pfizer/BioNTech, AstraZeneca, Sinovac, Moderna, and CanSino) in the Mexican population. Side effects of COVID-19 vaccines and clinical and demographic factors associated with low immunogenicity were also evaluated. A total of 242 SARS-CoV-2-vaccinated subjects were recruited. Pfizer/BioNTech and Moderna proved the highest percentage of inhibition in a mono-vaccine scheme. Muscular pain, headache, and fatigue were the most common adverse events. None of the patients reported severe adverse events. We found an estimated contagion-free time of 207 (IQR: 182–231) and 187 (IQR: 184–189) days for Pfizer/BioNTech and CanSino in 12 cases in each group. On the basis of our results, we consider that the emerging vaccination strategy in Mexico is effective and safe.https://www.mdpi.com/2075-4418/13/6/1194COVID-19SARS-CoV-2vaccinationneutralizing antibodiesCOVID-19 vaccinesELISA |
| spellingShingle | Fernando Alcorta-Nuñez Diana Cristina Pérez-Ibave Carlos Horacio Burciaga-Flores Miguel Ángel Garza Moisés González-Escamilla Patricia Rodríguez-Niño Juan Francisco González-Guerrero Adelina Alcorta-Garza Oscar Vidal-Gutiérrez Genaro A. Ramírez-Correa María Lourdes Garza-Rodríguez SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison Diagnostics COVID-19 SARS-CoV-2 vaccination neutralizing antibodies COVID-19 vaccines ELISA |
| title | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison |
| title_full | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison |
| title_fullStr | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison |
| title_full_unstemmed | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison |
| title_short | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison |
| title_sort | sars cov 2 neutralizing antibodies in mexican population a five vaccine comparison |
| topic | COVID-19 SARS-CoV-2 vaccination neutralizing antibodies COVID-19 vaccines ELISA |
| url | https://www.mdpi.com/2075-4418/13/6/1194 |
| work_keys_str_mv | AT fernandoalcortanunez sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT dianacristinaperezibave sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT carloshoracioburciagaflores sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT miguelangelgarza sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT moisesgonzalezescamilla sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT patriciarodrigueznino sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT juanfranciscogonzalezguerrero sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT adelinaalcortagarza sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT oscarvidalgutierrez sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT genaroaramirezcorrea sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison AT marialourdesgarzarodriguez sarscov2neutralizingantibodiesinmexicanpopulationafivevaccinecomparison |